Exhibiting immunogenicity as cancer vaccines in mouse tumor models and clinical studies, these synthetic SART3 peptides bind to various mouse and human MHC haplotypes.[41–43] Expression of SART3 antigen in oral cancer as a candidate of tumor antigens for use in specific immunotherapy was investigated by Fukuda. This evidence concerns the gene SART3 and lip and oral cavity carcinoma.